Search

Prouduct

AVANTOR ACE BIOANALYTICAL METHOD DEVELOPMENT UHPLC/HPLC COLUMN KITS

다공성 컬럼 - Normal phase Consumable > BIO Column > BIO Column
제품설명
- 액체 크로마토그래피에서 시료의 각 성분별 분리목적
- Method 개발을 위한 솔루션 

- 3가지 컬럼 제공: ACE C18-300, ACE C4-300 and ACE Phenyl-300 of specified dimensions
- HPLC hardware format with 275 bar / 4,000 psi pressure limit

 
연락처
레보딕스 031-790-1907
Column Dimensions 3 µm 5 µm
2.1 x 50 mm MDKB-3-0502U MDKB-5-0502U
2.1 x 75 mm MDKB-3-7502U MDKB-5-7502U
2.1 x 100 mm MDKB-3-1002U MDKB-5-1002U t
2.1 x 150 mm MDKB-3--1502U MDKB-5-1502U Pur
2.1 x 250 mm MDKB-5-2502U
3.0 x 50 mm MDKB-3-0503U MDKB-5-0503U
3.0 x 100 mm MDKB-3-1003U MDKB-5-1003U
3.0 x 150 mm MDKB-3-1503U MDKB-5-1503U
3.0 x 250 mm MDKB-5-2503U
4.6 x 50 mm MDKB-3-0546U MDKB-5-0546U
4.6 x 100 mm MDKB-3-1046U MDKB-5-1046U
4.6 x 150 mm MDKB-3-1546U MDKB-5-1546U
4.6 x 250 mm MDKB-5-2546U
  Bonded Phase SEPARATION MECHANISM AND RELATIVE STRENGTH 1
Hydrophobic Binding π-π Interaction Dipole-Dipole Hydrogen Bonding Shape Selectivity
ACE ADVANCED METHOD DEVELOPMENT KIT ACE C18 **** - - * **
ACE C18-AR **** *** (donor) * ** ***
ACE C18-PFP **** *** (acceptor) **** *** ****
ACE EXTENDED METHOD DEVELOPMENT KIT ACE SuperC18 **** - - - **
ACE C18-Amide **** - ** **** **/***
ACE CN-ES *** * *** ** *
ACE ULTRACORE METHOD DEVELOPMENT KIT ACE UltraCore SuperC18 *** - - - **
ACE UltraCore SuperPhenylHexyl ** *** (donor) * ** ***
ACE BIOANALYTICAL 300Å METHOD DEVELOPMENT KIT ACE C18-300 ** - - * *
ACE C4-300 * - - - -
ACE Phenyl-300 * ** (donor) * ** **
1 Approximate value determined by semi-quantitative mechanism weightings and/or by reference to other ACE phases using >100 characterising analytes.

 
  Bonded Phase SEPARATION MECHANISM AND RELATIVE STRENGTH 2
Partitioning Anionic Analyte Interactions Cationic Analyte Interactions H-bonding
Attraction Repulsion Attraction Repulsion
ACE HILIC ACE HILIC-A ** - *** **** - *
METHOD DEVELOPMENT KIT ACE HILIC-B *** **** - - *** *
  ACE HILIC-N **** - - - - ****
 
2 Approximate value determined by semi-quantitative mechanism weightings and/or by reference to other ACE phases using >50 characterising analytes.